Prediction of Pediatric Pharmacokinetics for CYP3A4 Metabolized Drugs: Comparison of the Performance of Two Hepatic Ontogeny Within a Physiologically Based Pharmacokinetic Model

Documenti analoghi

• Physiologically Based Pharmacokinetic Modeling of Lurasidone, an Antipsychotic Drug: Impact of CYP3A4 Polymorphisms and Hepatic Impairment on Exposure and Dose Optimization
  di: Seung‐Hyun Jeong, et al.
  Pubblicazione: (2026)
• Development and Evaluation of Ontogeny Functions of the Major UDP‐Glucuronosyltransferase Enzymes to Underwrite Physiologically Based Pharmacokinetic Modeling in Pediatric Populations
  di: Nashid Farhan, et al.
  Pubblicazione: (2024)
• Physiologically Based Pharmacokinetic (PBPK) Model to Predict the Magnitude of Drug–Drug Interaction Between Fezolinetant and CYP1A2 Inhibitors
  di: Mary P. Choules, et al.
  Pubblicazione: (2025)
• Physiologically Based Pharmacokinetic Modeling to Predict Drug–Drug Interactions of Soticlestat as a Victim of CYP Induction and Inhibition, and as a Perpetrator of CYP and P–Glycoprotein Inhibition
  di: Hongxia Jia, et al.
  Pubblicazione: (2025)
• Determination of Vatiquinone Drug‐Drug Interactions, as CYP450 Perpetrator and Victim, Using Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation
  di: Lucy Lee, et al.
  Pubblicazione: (2024)